News & Events

Check out our news section to keep up to date with any upcoming events which we will be attending as well as any exciting news within the pharmaceutical industry.

Cobra Biologics and Symbiosis Complete £4.8m Viral Vector Supply Chain Collaboration

Keele and Stirling, UK – Cobra Biologics (Cobra), an international contract development and manufacturing organisation (CDMO) focused on viral vector drug substance production, and Symbiosis Pharmaceutical Services (Symbiosis), a contract manufacturing organisation (CMO) specialising in the sterile manufacture of injectable viral vector drug products, today announced the successful completion of their collaboration to develop synergistic and world leading capabilities.Intended to accelerate the clinical… Read More

Symbiosis boosts business development team to support US growth

Stirling, UK – LEADING contract manufacturing organisation (CMO) Symbiosis Pharmaceutical Services has boosted its business development team to support its growth and continued development in the US.Business development manager Helen Caddy-Leach will be responsible for maximising the CMO’s presence in the US market, working with new and existing clients to ensure the continued successful delivery of sterile biomanufacturing services to US clients.Symbiosis,… Read More

vial filling services

Freeline, Symbiosis and the Cell and Gene Therapy Catapult secure collaborative funding from Innovate UK

London, UK – Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, has secured a collaborative grant of £1.3 million from Innovate UK to lead a supply chain model and delivery development project in partnership with Symbiosis Pharmaceutical Services (Symbiosis) and the Cell and Gene Therapy Catapult (CGTC). The project is intended to create a UK based novel viral vector supply… Read More

Q&A: Symbiosis: US FDA boost at Scottish aseptic viral vector plant

Colin MacKay, CEO of Symbiosis Pharmaceutical Services, recently took part in a Q&A interview with BioProcess Insider, discussing US Food and Drug Administration (FDA) approval and what it means for Symbiosis in terms of meeting industry demands now and post-Brexit.The article provides insight into the significance of US FDA accreditation, the Innovate UK grant and the challenges Brexit poses for Symbiosis and… Read More

Is it really location, location, location in sterile manufacturing?

The pharmaceutical industry is a truly global sector. Within drug development, clinical trials are now conducted all over the world, so does it really matter where your sterile product manufacturer is based?Away from factors such as locality, one of the key drivers of this decision will be the regulation of injectable medicines. So what are the regulatory differences between say Europe and… Read More

Symbiosis secures FDA viral vector process approval

Stirling, UK – SYMBIOSIS Pharmaceutical Services, a fast-growing specialist sterile manufacturing CDMO, has reported FDA approval for its viral vector manufacturing fill/finish process at its biologics manufacturing facility located in Scotland, UK.Symbiosis recently hosted a successful inspection by the United States Government Food and Drug Administration (FDA) for the aseptic manufacture of viral vector products for commercial supply into the U.S market… Read More

Cobra Biologics and Symbiosis awarded £1.9m ($2.5m USD) Innovate UK Grant

Keele and Stirling, UK, 1 February 2018: Cobra Biologics (Cobra), an international contract development and manufacturing organisation (CDMO) of biologics and pharmaceuticals, and Symbiosis Pharmaceutical Services (Symbiosis), a contract manufacturing organisation (CMO) specialising in sterile Fill Finish, today announced that they have been awarded a 16-month collaborative grant of £1.9m from Innovate UK.The grant will position the partner companies as globally recognised… Read More

Colin Mackay, CEO of Symbiosis

Steady growth in 2017 points to a successful year ahead for Symbiosis

Another year has passed here at Symbiosis HQ and I’m pleased to report that 2017 has been another strong year of sustained, profitable, growth for the company.Our underlying positive growth trend has continued, and aligns well with our strategic focus on developing the business in the North American market alongside our more established client base in Europe. Our efforts to proactively build… Read More

Get In Touch.


By ticking the box and clicking “Submit” below, you consent to receiving thought leadership, industry news, and invitations by email or other electronic means, which Symbiosis Pharmaceutical Services believes may be of value to you, relevant to your work and tailored to your professional profile and interests. This may include promotional information on products, services and events provided or organised by Symbiosis Pharmaceutical Services. By clicking the "Submit” button, you confirm that the information you have provided above is correct, and you agree to Symbiosis' processing of your personal data, including its transfer internationally and to third parties, in accordance with it's privacy policy.